Radioligand Services Target neuroimaging and radioligand development capabilities present cross-sell opportunities for large pharma and biotech partners pursuing early phase occupancy studies and biomarker validation in neurodegenerative and neuropsychiatric programs.

Clinical Imaging Scale Experience with multi-center quantitative imaging trials and large-scale Phase II-IV trials positions MNI as a preferred CRO-like partner for global studies, enabling collaborations with companies seeking expansive data collection and centralized imaging analytics.

Biomarker Advantage Biomarker development for presymptomatic and disease progression offers a route to align with companies aiming to de-risk pipelines, accelerate patient stratification, and support companion diagnostic strategies.

Strategic Partnerships As a specialized radioligand research and clinical imaging provider, MNI can form partnerships with larger pharmacovigilance, biomarker labs, or imaging core facilities within large pharma networks to expand capabilities and geographic reach.

Financial Signals With mid-range annual revenue and a focused niche, there is an opportunity to tailor scalable service packages and tiered engagement models for midsize biotechs and pharma companies seeking cost-effective, high-value neuroimaging solutions.